Following NAD Challenge, Factor Nutrition Permanently Discontinues Claim that Focus Factor is “America’s #1 Brain Health Supplement”

 

For Immediate Release 

Contact: Abby Hills, Director of Communications, BBB National Programs, 301.412.7769 / ahills@bbbnp.org 

 

NAD Finds No Reasonable Basis for Proposed Modified Claim, “America’s #1 Clinically Studied and Patented Brain Health Formula" 

 

New York, NY – May 6, 2020 – The BBB National Programs National Advertising Division (NAD) recommended that Factor Nutrition, LLC discontinue the claim that its Focus Factor brain health supplement is “America’s #1 Clinically Studied and Patented Brain Health Formula,” following a challenge by Quincy BioScience, Inc., maker of Prevagen brain health dietary supplement. 

NAD is an investigative unit of the advertising industry’s system of self-regulation and is a division of the BBB National Programs’ self-regulatory and dispute resolution programs. 

During the course of the proceeding, Factor Nutrition agreed to permanently discontinue the challenged claim “America’s #1 Brain Health Supplement,” which appeared on product packaging, labeling and in internet advertising. NAD, relying on the advertiser’s representation that the claim has been permanently discontinued, did not review the claim on its merits. The voluntarily discontinued claim will be treated, for compliance purposes, as though NAD recommended its discontinuance and the advertiser agreed to comply. 

The advertiser proposed a modification of its claim to read: “America’s #1 Clinically Studied and Patented Brain Health Formula,” and NAD assessed whether the evidence in the record was sufficient to substantiate the claim. 

First, NAD determined that the evidence in the record was insufficient to support the health-related product efficacy claim that Focus Factor is “America’s #1 Clinically Studied . . . Brain Health Supplement.” The evidence in the record demonstrated that other brain health supplements (including Prevagen) outsell Focus Factor, however, there was limited evidence in the record regarding which of those products had been clinically studied or the reliability of those studies. NAD noted that in order to support its claim the advertiser would have needed to show that, for any products that outsell Focus Factor, testing on those products is lacking or is insufficiently reliable to demonstrate any brain health benefits.  

Further, with regard to the latter portion of the claim, that Focus Factor is “America’s #1 . . . Patented Brain Health Formula,” the advertiser argued that the claim is supported because Focus Factor has a patent on the product’s formula covering “brain health and mental performance,” whereas the challenger does not hold a patent on Prevagen’s finished product but, rather, only on certain ingredients in its product. While the advertiser’s Focus Factor supplement has a 2012 patent, NAD noted that the product’s Supplement Facts lists ingredients not mentioned in the patent’s list of ingredients – Vitamins A, C and D, and Riboflavin – calling into question whether its patent covers the entire finished formula. NAD also determined that even if it is literally true that Focus Factor is the #1 selling product that has (1) a patent on its finished formula and (2) a patent specifically for brain health, consumers would be unlikely to make the nuanced distinction between the advertiser’s product and the challenger’s (and other) brain health supplements with patented key ingredients. Rather, consumers would likely still take away the overarching – but unsupported message – that Focus Factor is America’s #1 selling brain health supplement that is also patented. 

For these reasons, NAD determined that the advertiser did not provide a reasonable basis for its proposed modified claim that Focus Factor is “America’s #1 Clinically Studied and Patented Brain Health Formula,” and recommended that the claim be discontinued.  

In its advertiser’s statement, Factor Nutrition was disappointed with certain of NAD’s findings, but agreed to comply with NAD’s recommendations.   

### 

About the National Advertising Division: National Advertising Division (NAD), a division of BBB National Programs, provides independent self-regulation overseeing the truthfulness of advertising across the U.S. NAD reviews national advertising in all media and its decisions set consistent standards for truth and accuracy.  

About BBB National Programs: BBB National Programs fosters trust, innovation, and competition in the marketplace through the development and delivery of cost-effective, third-party self-regulation, dispute resolution and other programs. BBB National Programs is the home of industry self-regulatory and dispute resolution programs designed to resolve business issues and advance shared objectives by responding to marketplace concerns to create a better customer experience. To learn more about industry self-regulation, please visit: BBBNP.org

 

Latest News

Press Release

BBB National Programs National Advertising Division Launches Expedited Fast-Track SWIFT Lane Designed to Address Misleading Advertising Disclosures

New York, NY – November 9, 2021 – Mindful of recent Federal Trade Commission (FTC) actions, BBB National Programs today announced a new, streamlined lane of the expedited Fast-Track SWIFT challenge submission process, one designed specifically to address the prominence and sufficiency of...

Read the Release
Press Release

Media Advisory: FTC Commissioner Rebecca Slaughter to Keynote National Advertising Division “Future of Ad Law” 2021 Annual Conference

New York, NY – September 21, 2021 – In its 50th anniversary year, the National Advertising Division (NAD) of BBB National Programs will host the NAD 2021 Annual Conference virtually next week, running Wednesday, September 29 through Friday, October 1. Members of the media are invited to cover NAD 2021 with...

Read More
Press Release

Children’s Advertising Review Unit Issues Revised Guidelines for Responsible Advertising to Children, Effective January 1, 2022

McLean, VA – July 29, 2021 – BBB National Programs’ Children’s Advertising Review Unit (CARU) today announced the issuance of the revised CARU Advertising Guidelines, widely recognized industry standards to assure that advertising directed to children is not deceptive, unfair, or inappropriate for its intended...

Read the Press Release
Press Release

U.S.-Based BBB National Programs Announced as Winner for “Best Sectoral Initiative” by International Council of Advertising Self-Regulation

On 15 June 2021, the International Council for Advertising Self-Regulation (ICAS) announced the winners of its second edition of the ICAS Global Awards. The objective of the ICAS Awards is to reward initiatives that contribute to responsible marketing practices and a more effective and impactful...

Read the Press Release